Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Shrinking team NBB
FTE fell two years in a row, from 38.9 to 9.6.
-
Busy address KBO
88 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
EXPLEO LIFE SCIENCES BELGIUM from Elsene, company number BE0890368245, closed financial year 2025 with a result of € -46,074 after tax. For that financial year EXPLEO LIFE SCIENCES BELGIUM recorded a gross margin of € 908,980 and equity of € 338,621. Compared with financial year 2024, the result moved from € -393,670 to € -46,074. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 22, 2026.
€ 338,621
▲ 57% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -46,074
▲ 88 % less loss than in 2024
Profit after tax over the fiscal year.
Loss, nothing to pay out
Reserves fell to € 43,925.
People and assets in 2025
9.6
▼ 10.6 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 946,841
▼ 52% vs 2024
€ 98,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1,621
▼ 57% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 249,256
▼ 32% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 81,926
▼ 52% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 2,821,658 | € 2,927,851 | € 1,650,305 | € 908,980 | ▼ 45% |
| Profit after taxes | € -11,887 | € -230,409 | € -393,670 | € -46,074 | ▲ € 347,595 |
| Equity | € 839,593 | € 609,184 | € 215,515 | € 338,621 | ▲ 57% |
| Total debts | € 1,140,389 | € 882,959 | € 1,032,920 | € 550,535 | ▼ 47% |
| Cash | € 47,940 | € 219,372 | € 176,921 | - | |
| Retained profit | € -60,407 | € -290,816 | € -684,485 | € 43,925 | ▲ € 728,411 |
| Balance sheet total | € 2,029,983 | € 1,542,144 | € 1,298,434 | € 939,156 | ▼ 28% |
| Employees (FTE) | 39.8 | 38.9 | 20.2 | 9.6 | ▼ 10.6 |
Key figures of EXPLEO LIFE SCIENCES BELGIUM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to EXPLEO LIFE SCIENCES BELGIUM?
What happened at EXPLEO LIFE SCIENCES BELGIUM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 46,074. Source: NBB ↗
- New establishment in Brussel. KBO
- Damien LASOU became a director. NBB
- Start of the company according to the CBE. KBO
- New establishment in Elsene. KBO
In short
From € 11,887 loss in 2022 to € 46,074 loss in 2025.
Paid € 42,472 in corporate taxes since 2022.
On average € 94,700 of value added per employee in 2025.
A new publication or filing at EXPLEO LIFE SCIENCES BELGIUM? We notify you, reason included.
Follow EXPLEO LIFE SCIENCES BELGIUMDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind EXPLEO LIFE SCIENCES BELGIUM is Damien LASOU. The shares are held by EXPLEO SAS (100%).
Directors
According to the 2025 annual accounts
Damien LASOU
Director
since 2022
Shareholders
EXPLEO SAS
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Louizalaan 240 box 14
1050 Elsene
Louizalaan 14
1050 Elsene
Active since 15 June 2007
Koloniënstraat 11
1000 Brussel
Active since 28 August 2024
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 88 companies are registered at this address.
All companies at this address →Plan Immo
€ -5,127 gross margin · 2025
SAPEC
Immobilière Steynhoeve
€ 18,652 gross margin · 2025
Financiële Vennootschap Frédéric Jacobs-Financière Frédéric Jacobs
€ -23,234 gross margin · 2025
WALT LOUISE
€ 208,349 gross margin · 2024
+83 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0890.368.245
- VAT number
- BE 0890.368.245
- Registered office
- Louizalaan 240 bus 14, 1050 Elsene
- Names & denominations
- EXPLEO LIFE SCIENCES BELGIUM
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 27 June 2007
- Peppol
- Active · Active since 12 Dec 2025
- Activities · NACE
Activiteiten van ingenieurs en aanverwante technische adviseurs, exclusief landmeters-experts
Markt- en opinieonderzoek
Marktonderzoekbureaus